References-

1. Ahn, B.-Z.; Sok, D.-E, (1996), "2-Substituted Naphthazarins; Synthesis and Antitumor Activity" *Curr.Pharm.Des*., 2, 247.
2. Bailly, C, (2003), "Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs", *Crit. ReV. Oncol. Hematol*, 45, 91
3. Bohm, M.; Sturzebecher, J.; Klebe, G, (1999), "Three-dimensional quantitative structure–activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.", *J. Med. Chem.*, *42*, 458-477
4. C. Hansch and E. J. Lien (1968), "An analysis of the structure-activity relationship in the adrenergic blocking activity of the beta-haloalkylamines", *Biochem. Pharmacol.*, *17*, 709.
5. Dallavalle, S.; Ferrari, A.; Biasotti, B.; Merlini, L.; Penco, S.; Gallo, G.; Marzi, M.; Tinti, M. O.; Martinelli, R.; Pisano, C.; Carminati, P.; Carenini, N.; Beretta, G.; Perego, P.; De Cesare, M.; Pratesi, G.; Zunino, F, (2001), "Novel 7 oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.", *J. Med. Chem*, 44, 3264.
6. Feixas F, Lindert S, Sinko W, McCammon JA, (2014), "Exploring the role of receptor flexibility in structure-based drug discovery", *Biophys Chem*, 186:31-45
7. G. Charvin,T.R. Strick, D. Bensimon and V. Croquette, (2005), "Tracking Topoisomerase Activity At The Single-Molecule Level", *Annu. Rev. Biophys. Biomol. Struct*. 34:201–19.
8. Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. M., (1962), "Correlation of Biological Activity of Phenoxyacetic Acids with Hammett Substituent Constants and Partition Coefficients", *Nature*, 194, 178.
9. Hansch, C.; Verma, R. P, (2007), "20-(S)-camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study.", *Chem Med Chem*, 2, 1807.
10. James C. Wang, (1996), "DNA Topoisomerases", *Annual Reviews Biochem*, 65:635-92
11. James C. Phillips, Rosemary Braun, Wei Wang, James Gumbart, Emad Tajkhorshid, Elizabeth Villa, Christophe Chipot, Robert D. Skeel, Laxmikant Kale, and Klaus Schulten, (2005), "Scalable molecular dynamics with NAMD".

Journal of Computational Chemistry, 26:1781-1802.

12. Kim, D.-K.; Ryu, D. H.; Lee, J. Y.; Lee, N.; Kim, Y.-W.; Kim, J.- S.; Chang, K.; Im, G.-J.; Kim, T.-K.; Choi, W.-S, (2001), "Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues", *J. Med. Chem*, 44, 1594.
13. Kim, Y.; You, Y.-J.; Ahn, B.-Z., (2001), "Naphthazarin derivatives (VIII): Synthesis, inhibitory effect on DNA topoisomerase-I, and antiproliferative activity of 6-(1-acyloxyalkyl)-5,8-dimethoxy-1,4-naphthoquinones", *Arch.Pharm*., 334, 318.
14. Legarza, K.; Yang, L.-X, (2005), "Novel camptothecin derivatives.", In *ViVo*, 19, 283.
15. Leu, Y.-L.; Roffler, S. R.; Chern, J.-W, (1999), "Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)" *J. Med. Chem*, 42, 3623.
16. Li, M.-J.; Jiang, C.; Li, M.-Z.; You, T.-P, (2005), "QSAR studies of 20(S)-camptothecin analogues as antitumor agents", *J. Mol. Struct.: THEOCHEM* 2005, 723, 165.
17. Li, Q.-Y.; Zu, Y.-G.; Shi, R.-Z.; Yao, L.-P, (2006), "Review camptothecin: current perspectives", *Curr. Med. Chem*, 13, 2021.
18. Lorence, A.; Nessler, C. L, (2004), "Camptothecin, over four decades of surprising findings" *Phytochemistry*, 65, 2735.
19. Lu, A.-J.; Zhang, Z.-S; Zheng, M.-Y.; Zou, H.-J.; Luo, X.-M; Jiang, H.-L, (2007), "3D-QSAR study of 20 (S)-camptothecin analogs", *Acta Pharmacol. Sin*, 28, 307.
20. Qing-Yong Li, Yuan-Gang Zu, Rong-Zhen Shi and Li-Ping Yao, (2006) "Review camptothecin: current perspectives", *Curr Med Chem* ;13(17):2021-39.
21. Rajeshwar P. Verma and Corwin Hansch (2009), "Camptothecins: a SAR/QSAR study", *Chem Rev*;109 (1):213-35
22. Rajeshwar P. Verma, (2005), "Understanding topoisomerase I and II in terms of QSAR", *Bioorganic & Medicinal Chemistry*, 13 1059–1067.
23. Redinbo, M. R.; Stewart, L.; Kuhn, P.; Champoux, J. J.; Hol, W. G, (1998), "Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.", *J.Science*, 279, 1504.
24. Ren J, Li J, Shi F, Wang X, He JH, Xu YC, Zhang NX, Xiong B, Shen JK, (2013),

"Progress in the fragment-based drug discovery", *Yao Xue Xue Bao*, 48(1):14-24

25. Rodriguez-Berna G, Cabañas MJ, Mangas-Sanjuán V, Gonzalez-Alvarez M, Gonzalez-Alvarez I, Abasolo I, Schwartz S Jr, Bermejo M, Corma A, (2013), "Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives", *ACS Med Chem Lett*, 4(7):651-5
26. Roy, K. (2007). "On some aspects of validation of predictive quantitative structure-activity relationship models". *Expert Opin. Drug Discov*. 2 (12): 1567–1577.
27. S. Ajmani, K. Jadhav, S.A. Kulkarni, (2009), "Group-Based QSAR (GQSAR): mitigating interpretation challenges in QSAR", *QSAR Comb. Sci*. 28 36–41.
28. Song, G.-Y.; Kim, Y.; Zheng, X.-G.; You, Y.-J.; Cho, H.; Chung, J.-H.; Sok, D.-E.; Ahn, B.-Z. (2000), "Naphthazarin derivatives (IV): synthesis, inhibition of DNA topoisomerase I and cytotoxicity of 2- or 6-acyl-5,8-dimethoxy-1, 4-naphthoquinones.", *Eur. J. Med. Chem*., 35, 291.
29. Tanya Singh, D. Biswas, B. Jayaram (2011), "AADS - An automated active site Study", *Chem. Rev*, 109, 213–235
30. Ulukan, H.; Swaan, P.W. (2002), "Camptothecins, a review of their chemotherapeutical potential". *Drugs*, *62(2)*, 2039–2057.
31. Wall, M. E, (1998), "Camptothecin and taxol: discovery to clinic", *Med. Res. ReV*, 18, 299.
32. Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M, (1993), "Plant antitumor agents. 30 Synthesis and structure activity of novel camptothecin analogs", *J. Med. Chem*. 36, 2689.
33. Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.I.; Sim, G.A. (1996) "Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate", *J. Am. Chem. Soc*, 88, 3888–3890.
34. Wang, X.; Zhou, X.; Hecht, S. M, (1999), "Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex." *Biochemistry*, 38, 4374.
35. Wang MJ, Liu YQ, Chang LC, Wang CY, Zhao YL, Zhao XB, Qian K, Nan X, Yang L, Yang XM, Hung HY, Yang JS, Kuo DH, Goto M, Morris-Natschke SL, Pan SL, Teng CM, Kuo SC, Wu TS, Wu YC, Lee KH, (2014), "Design, Synthesis,

Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin as Potent Antitumor Agents", *J Med Chem*, [Epub ahead of print].

36. Wold S, Eriksson L (1995). "Statistical validation of QSAR results". In Waterbeemd, Han van de. Chemometric methods in molecular design. *Weinheim: VCH*. 309–318.
37. Xiangshu Xiao and Mark Cushman, (2005), "An Ab Initio Quantum Mechanics\ Calculation that Correlates with Ligand Orientation and DNA Cleavage Site Selectivity in Camptothecin-DNA-Topoisomerase I Ternary Cleavage Complexes", *J Am Chem Soc*.; 127(28): 9960–9961
38. Yoshikawa, M.; Ikegami, Y.; Hayasaka, S.; Ishii, K.; Ito, A.; Sano, K.; Suzuki, T.; Togawa, T.; Yoshida, H.; Soda, H.; Oka, M.; Kohno, S.; Sawada, S.; Ishikawa, T.; Tanabe, S, (2004), "Novel camptothecin analogues that circumvent ABCG2 associated drug resistance in human tumor cells", *Int. J. Cancer*, 110, 921.
39. Zhao XB, Goto M, Song ZL, Morris-Natschke SL, Zhao Y, Wu D, Yang L, Li SG, Liu YQ, Zhu GX, Wu XB, Lee KH, (2014), "Design and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents", *Bioorg Med Chem Lett*, [Epub ahead of print]
40. Zu, Y.-G.; Li, Q.-Y.; Fu, Y.-J.; Wang, W, (2004), "Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin.", *Bioorg. Med. Chem. Lett*, 14, 4023.